Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04675710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion pushed from Oct 30, 2026 to Oct 30, 2028Secondary endpoints: details revised at 3 of 8 entries · Study description revised · Eligibility criteria expanded, about 4 wordsShow 3 more changesShow less
Secondary endpoints: details revised at 3 of 8 entries
Study description revised
Eligibility criteria expanded, about 4 words
Minor4 versionsRe-verified since Aug 12, 2025, no change to tracked fieldsv19-v22
MinorTrial status: Recruiting to Active, Not RecruitingSite details revised at 6 of 6 sitesv18Show 1 more changeShow less
Site details revised at 6 of 6 sites
MinorRe-verified, no change to tracked fieldsv17
NotablePrimary and study completion dates: Jun 30, 2024 to Oct 30, 2026v16
Show 14 earlier versionsHide 14 earlier versions
MinorSecondary endpoints: details revised at 1 of 8 entriesEligibility criteria expanded, about 1 word · Study description expanded, about 2 wordsv15Show 2 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Jan 31, 2021 to Jun 24, 2021 · Site details revisedv2Show 2 more changesShow less
Start date changed from estimate of Jan 31, 2021 to Jun 24, 2021
Site details revised
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in cell growth. It may increase the growth and spread of tumor cells. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab, dabrafenib, and trametinib may help to control BRAF V600E-mutated anaplastic thyroid cancer when given before surgery.